Frontlight ResearchEarly access
TerminatedNo phase
Transnasal Induction of Normothermia for Neurogenic Fever
Key facts
- Who runs it
- CoolTech LLC
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 9 people enrolled
- Started
- 21 Nov 2023
- Ended
- 30 Nov 2025
- Type of study
- Interventional
- Treatments tested
- Transnasal Thermal Regulating Device
- Record updated
- 26 January 2026
- Why it stopped
- Insufficient accrual
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Admitted to an Intensive Care Unit for a planned stay of at least 24 hours with a diagnosis of ischemic or hemorrhagic stroke, seizure, or metabolic encephalopathy
- Ages 18-85 years, inclusive
- Patient has fever ≥ 38.3°C and ≤ 38.9°C at the time of treatment initiation
- Patient is orally intubated or has tracheostomy tube and is mechanically ventilated
- Glasgow Coma Scale score of 3-11, inclusive
- Must have informed consent from the patient or the legally authorized representative (LAR) making decisions for the patient
Who cannot take part
- Prior skull-base surgery
- Patient is in airborne/droplet disease isolation protocol
- Any condition for which transnasal air flow would be contraindicated
- Intubation is contraindicated
- Weight of ≤ 100lb or ≥ 250lb
- Active/ongoing epistaxis
- Known or suspected pregnancy
- Participation in another ongoing investigational study
- Prisoners and/or patients for whom no LAR is available
- Patient is or suspected to be immunocompromised
- Nasal septal deviations (per standard of care CT scan; any degree)
- Chronic rhinosinusitis
- Traumatic brain injury
- Penetrating cranial trauma
- Recent nasal trauma or anterior base skull fracture
- Refractory hypoxemia (partial pressure of oxygen in arterial blood (paO2) below 60 torr or oxyhemoglobin saturation below 90% despite endotracheal intubation, mechanical ventilation, and provision of supplemental oxygen of up to 0.60)
- Refractory hypercarbia (partial pressure of carbon dioxide in arterial blood (paCO2) above 50 torr despite endotracheal intubation and conventional mechanical ventilation)
Where in United States
- University of Maryland Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
The objective of this study is to evaluate the efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.
The group in the trial
- Transnasal Thermal Regulating DeviceTreatment being tested
Consented subjects who develop fever will undergo cooling via transnasal thermal regulating device for a period of 24 hours
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Open Label Clinical Trial to Evaluate the Safety and Efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in Inducing Normothermia for Neurogenic Fever in an Intensive Care Setting
- Record updated
- 26 January 2026